Roche’s BTK inhibitor succeeds in a Phase II MS trial

Roche’s fenebrutinib achieved positive results in a Phase II clinical trial in patients with relapsing forms of multiple sclerosis (RMS), meeting the trial’s primary and secondary endpoints.